Fox Run Management L.L.C. Takes $369,000 Position in Guardant Health, Inc. (NASDAQ:GH)

Fox Run Management L.L.C. bought a new position in Guardant Health, Inc. (NASDAQ:GH) during the fourth quarter, Holdings Channel reports. The firm bought 12,084 shares of the company’s stock, valued at approximately $369,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Intech Investment Management LLC bought a new position in Guardant Health during the third quarter valued at $754,000. Cerity Partners LLC lifted its holdings in shares of Guardant Health by 54.6% in the 3rd quarter. Cerity Partners LLC now owns 195,008 shares of the company’s stock valued at $4,473,000 after acquiring an additional 68,883 shares during the last quarter. Advantage Alpha Capital Partners LP purchased a new position in Guardant Health in the third quarter worth about $343,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Guardant Health by 6.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 28,986 shares of the company’s stock worth $665,000 after acquiring an additional 1,844 shares during the last quarter. Finally, Verition Fund Management LLC raised its position in Guardant Health by 220.6% during the third quarter. Verition Fund Management LLC now owns 37,641 shares of the company’s stock valued at $863,000 after purchasing an additional 25,900 shares during the period. 92.60% of the stock is owned by institutional investors.

Guardant Health Trading Down 1.3 %

Shares of NASDAQ:GH opened at $45.84 on Thursday. The company has a market capitalization of $5.66 billion, a PE ratio of -12.88 and a beta of 1.50. Guardant Health, Inc. has a 12-month low of $15.81 and a 12-month high of $50.89. The business’s fifty day simple moving average is $44.37 and its 200-day simple moving average is $34.03.

Guardant Health (NASDAQ:GH) last posted its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The company had revenue of $201.81 million during the quarter, compared to analysts’ expectations of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. Research analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on GH. Raymond James reissued an “outperform” rating and set a $59.00 target price (up previously from $39.00) on shares of Guardant Health in a research report on Friday, February 21st. Canaccord Genuity Group increased their target price on shares of Guardant Health from $42.00 to $60.00 and gave the company a “buy” rating in a research note on Monday, February 24th. JPMorgan Chase & Co. lifted their price target on shares of Guardant Health from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Guggenheim reaffirmed a “buy” rating and set a $56.00 target price on shares of Guardant Health in a research note on Monday, February 24th. Finally, Morgan Stanley raised their price target on Guardant Health from $42.00 to $52.00 and gave the stock an “overweight” rating in a research note on Thursday, March 6th. Twenty equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $48.95.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.